Treatment of patients with advanced medullary thyroid carcinoma (MTC) is still a challenge. For more than 2 decades it is known that cholecystokinine-2 receptor (CCK2R) is a promising target for the treatment of MTC with radiolabeled minigastrin analogues. Unfortunately, kidney toxicity precluded their therapeutic application so far. In 6 consecutive patients we evaluated with advanced 3D dosimetry whether improved minigastrin analogue 177 Lu-DOTA-(DGlu) 6 -Ala-Tyr-Gly-Trp-Nle-Asp-PheNH 2 ( 177 Lu-PP-F11N) is a suitable agent for the treatment of MTC.
INTRODUCTION
effect. Another approach to reduce nephrotoxicity is to modify the compound itself: Amino acid chains with more than 5 glutamic acids in their sequence play an important role in the kidney reuptake mechanism and may reduce kidney uptake (10, 11) . Such an approach was implemented by several groups and resulted in the development of a library of improved radiolabeled minigastrin analogues (12) (13) (14) (15) (16) (17) . Some of these new compounds show higher tumor uptake, higher tumor-to-kidney uptake ratios and higher serum stability, compared to the previously developed minigastrin analogues. One of the most promising new compounds is PP-F11N (DOTA-(DGlu) 6 -Ala-Tyr-Gly-Trp-Nle-Asp-PheNH 2 ) which can be labeled with Lutetium-177, a widely used radionuclide that has not only excellent therapeutic properties but also a gamma ray component that allows acquisition of good quality images for a personalized treatment approach (theranostics), as well as dosimetry studies (16) .
Here, we present the first-in-human results of 177 Lu-PP-F11N. Primary endpoint was the proof of CCK2R specific in vivo targeting and visualization of MTC metastases in correlation with histology, in vitro autoradiography or 18 F-DOPA PET/CT as standard of comparison. Secondary endpoints were safety, biodistribution, pharmacokinetics and radiation dosimetry after injection of a test dose of 177 Lu-PP-F11N with SG and without kidney protection in the same patient in a random cross-over order.
MATERIALS AND METHODS

Study Design and Patients
This is a prospective, randomized cross-over phase 0 single center study (clinicaltrials.gov: NCT02088645). The study was approved by the Institutional Review Board and all patients signed a written informed consent in accordance with the Declaration of Helsinki.
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The main inclusion criteria were: histologically confirmed MTC with or without thyroidectomy and either elevated levels of calcitonin (> 100 pg/ml; respectively 29.2 pmol/l) and/or calcitonindoubling time < 24 months. Patients who had received Vandetanib less than 3 weeks before the study and patients with reduced kidney or bone marrow function (calculated glomerular filtration rate < 60 ml/min / 1.73 m2 body surface, thrombocytes < 70'000/μl, leucocytes < 2'500/μl, hemoglobin < 8 g/dl) were not included.
Preparation of 177 Lu-PP-F11N
177 Lu-PP-F11N was produced according to good manufacturing practice by the Paul Scherrer Institute Villigen, Switzerland. The precursor peptide PP-F11N (2031.5 g/mol, GMP grade quality, piCHEM GmbH, Graz, Austria) is carrying a DOTA moiety on its N-terminal end, which allows stable chelation of Lutetium-177. GMP grade no carrier-added 177 LuCl 3 (EndolucinBeta) was provided by ITG Isotope Technologies Garching GmbH, Garching, Germany. Radiolabeling of 177 Lu-PP-F11N was done in a synthesis module (PharmTracer by Eckert & Ziegler, Berlin, Germany). The reaction mixture, composed of 100 µg PP-F11N in aqueous 0.25 M ammoniumacetate buffer pH 5.5 (trace pure reagents, Sigma Aldrich, Buchs, Switzerland) and sodium ascorbate (USP grade) was incubated for 40 min at 60 °C with 1.7 GBq of EndolucinBeta. The reaction mixture was purified via C-18 SepPak column and sterile filtered into a bulk vial. The bulk product contained 20.9 mL 0.9 % saline, 1.25 mL ethanol, 1.75 mL water for injection, 0.1 ml DTPA (200 mg/mL), 250 mg sodium-ascorbate and 177 Lu-PP-F11N (total volume of 24 mL).
After dispensing via a second sterile filter and taking aliquots for QC, the resulting product vial contained 20 ± 2 mL of final product tested for compliance with specifications (radiochemical purity: ≥ 95%; 177 Lu-DTPA: ≤ 2%; peptide content: < 100 µg of total PP-F11N; endotoxins: ≤ 175 EU). The product contained about 1 GBq of radioactivity at the end of shelf life, which is 24 h.
Injection
Patients received about 1 GBq 177 Lu-PP-F11N with and without SG in a random cross-over order within 4 weeks. Administration of SG (Physiogel®, B. Braun Medical AG, Sempach, Switzerland) was performed according to the IAEA, EANM, SNMMI guideline for PRRT (18) , starting with a bolus dose of 6 ml/kg body weight/min 10 min before the start of the injection of 177 Lu-PP-F11N. After termination of 177 Lu-PP-F11N infusion, SG infusion was continued at a lower rate of 0.02 ml/kg body weight/min for 3 h.
Vital signs were recorded for 24 h and a 12-lead electrocardiogram was done before and 2 h after each injection. Clinical laboratory tests (hematology, biochemistry) were assessed until 12 weeks after the second injection. Adverse events were recorded and graded according to CTCAE 4.03.
Biodistribution, Pharmacokinetics and Dosimetry
Whole-body planar images and SPECT from neck to pelvis were performed on a calibrated by Universitaetsbibliothek Bern on January 8, 2020. For personal use only. jnm.snmjournals.org Downloaded from Dosimetry of tumors, stomach and kidneys with and without co-administration of SG was performed with the Siemens Dosimetry Research Tool software version 5.4 (DRT, Siemens Medical Solutions, USA). DRT enables two methods for calculation of radiation dose: Voxelbased 3D dose kernel approach and a volume-based MIRD procedure, using quantitative SPECT/CT datasets with volumes of interest (VOIs) to create a time-activity fit (19) . In our study the more established volume-based MIRD procedure was used. OLINDA/EXAM 1.0 software (Vanderbilt University, TN, USA) was used for the radiation dose calculation of the large intestine, bladder and the red bone marrow, see supplemental data. This is a 2D method based on planar images or blood sampling, using a blood-to-red-marrow activity by Universitaetsbibliothek Bern on January 8, 2020. For personal use only. jnm.snmjournals.org Downloaded from concentration ratio of 1, as recommended by the European Association of Nuclear Medicine (20) . Fresh frozen tissue samples of one patient were available for in vitro autoradiography. In vitro CCK2R autoradiography was performed as described before (7) . The sections were incubated with 6 x 10 5 cpm/ml of indium-111 labeled PP-F11N (45 MBq/nmol). In order to assess nonspecific binding, an adjacent section of the same specimen was incubated in tracer solution containing additionally 200 nM of non-radioactive human gastrin (BACHEM, Bubendorf, Switzerland). The slides were then exposed to Biomax MR films (Carestream Health, Stuttgart, Germany) for 4 days. For signal quantification, a separate calibration curve, based on standard samples containing known amounts of radioactivity was recorded for each experiment.
Standard for Comparison
Subsequently, the autoradiograms were analyzed using MCID software (InterFocus, Linton, UK).
For histopathological evaluation and localization of autoradiographic signal, adjacent slices were hematoxylin-eosin-stained.
Statistical Analysis
All variables were analyzed descriptively. Paired sign t-test, with a p-value <0.05 denoting statistical significance, was used to compare results obtained with and without SG (matched pairs).
RESULTS
Patients
Six consecutive patients with histologically proven MTC were screened and participated in the study. They all completed the study and were included in the proof of principle, safety, pharmacokinetic and dosimetry evaluation. All patients have had thyroidectomy previously. For further baseline demography and disease characteristics see Supplemental Table 1 .
Proof of Principle
After infusion of 1040 ± 70 MBq (mean ± standard deviation; range: 915-1226 MBq) 177 Lu-PP- accumulation in lymph node metastases ( Fig. 3 ). One lymph node metastasis with a maximal diameter of 8 mm and 40% tumor involvement was not visible with SPECT/CT, but showed specific and intense 111 In-PP-FF11N uptake in vitro (Supplemental Fig. 1 ). The minimal size among detectable tumors with SPECT/CT was 8 mm, see Fig. 1 .
Safety, Pharmacokinetics and Dosimetry
The short infusion (duration range: 4-6 minutes) of 79.3 ± 10.5 µg (mean ± SD, range: 67.0-94.5 µg) 177 Lu-PP-F11N was well tolerated with only grade 1 toxicity (Table 2) .
by Universitaetsbibliothek Bern on January 8, 2020. For personal use only. jnm.snmjournals.org Downloaded from Blood sampling of 177 Lu-PP-F11N revealed a bi-exponential blood clearance with an α half-life of 11 ± 3.3 min (with SG) versus 10.8 ± 5.4 min (without SG) and a β half-life of 162 ± 12 min versus 163 ± 14 min (mean ± SD); approximately 45% of the administered activity was cleared in the α phase. SG infusion starting 10 min before injection of 177 Lu-PP-FF11N did not significantly reduce renal absorbed dose: median (IQR) absorbed dose was 0.11 (0.07-0.13) Gy/GBq without SG and 0.06 (0.05-0.09) Gy/GBq with SG, p = 0.38 (two-sample paired sign test). The small amount of absorbed dose to the kidneys indicates low retention of 177 Lu-PP-F11N in the kidneys despite its predominant renal excretion (Fig. 2) . The highest absorbed dose was determined for the tumors and stomach: median (IQR) absorbed dose without SG was 0.88 (0.85-1.04) Gy/GBq for tumors and 0.42 (0.25-1.01) Gy/GBq for the stomach, resulting in a median (IQR) tumor-to-stomach dose ratio of 3.34 (1.14-4.7), see Table 1 . Blood sampling revealed a comparable median bone marrow dose with and without SG (0.032 and 0.028 Gy/GBq, respectively, Table 1 ). A summary of dosimetry results of all organs is given in Supplemental Table 2 .
DISCUSSION
The main findings of this phase 0 clinical trial can be summarized as follows: 1) 177 Lu-PP- (22) . On the other hand, in vitro autoradiography studies have shown a higher incidence of CCK2R than SST2R expression in MTC: iodine-125 labeled CCK2R agonist showed specific binding in >90% of MTC versus <30% with iodine-125 labeled SST2R agonist (7, 23) . Furthermore, radiation doses to organs such as kidneys and bone marrow were at least 3 times less with 177 Lu-PP-F11N than with 177 Lu-DOTATATE (22) . Based on our dosimetry study, fractionated treatment with a cumulative activity of 50 GBq 177 Lu-PP-F11N should be possible without surpassing the maximal tolerated dose to the stomach, which is estimated to be 50 Gy based on external beam radiotherapy studies (24) . Indeed, the 3 rd quartile of the 177 Lu-PP-F11N absorbed dose to the stomach was 1 Gy/GBq. A cumulative activity of 50 GBq could potentially result in a mean absorbed tumor dose of 50 x 0.9 Gy (~45 Gy) or 50 x 3.6 Gy (~180 Gy) for patient 2, who showed the highest tumor absorbed dose.
Acute toxicity after injection of 67.0-94.5 µg 177 Lu-PP-F11N was low and within the range of adverse reactions known from the CCK2R agonist pentagastrine (calcitonin stimulation test) or other minigastrin analogues (8) . Radiation induced toxicity was not observed after a cumulated activity of ~2 GBq 177 Lu-PP-F11N.
Calculated kidney radiation doses were low and resulted in higher median tumor-to-kidney radiation dose ratios, compared to the commonly used therapeutic radiotracer 177 Lu-DOTATATE by Universitaetsbibliothek Bern on January 8, 2020. For personal use only. jnm.snmjournals.org Downloaded from (11.6 versus 1.6) (22) . In contrast to DTPA-Glu 1 -minigastrin (9), the co-administration of SG did not significantly reduce the tumor-to-kidney dose ratio in our study. Therefore, nephroprotection with SG in combination with 177 Lu-PP-F11N is not beneficial and can be omitted, as kidney doses are already low. The stomach received the highest calculated organ radiation dose and is therefore most likely the dose limiting organ. This has been reported for CCK2R ligands before (8) and can be explained by specific binding of 177 Lu-PP-F11N to the CCK2R on neuroendocrine cells in the gastric mucosa, mainly enterochromaffine-like cells (25) . Interestingly, stomach radiation doses in our patients were heterogeneous (0.18 -2.07 Gy/GBq). The patient with the highest stomach dose (patient 5) had history of medication with proton pump inhibitors. The patient with the lowest dose (patient 4) received enteral tube feeding formula. Therefore, it can be speculated that gastric acidity and activity (digestion) might have a relevant effect on the stomach uptake. This would be in line with reported increase of enterochromaffine-like cells density and the thickness of gastric mucosa after chronic acid suppression by proton pump inhibitors (25) . Radiation doses of the remaining organs, including bone marrow, were low and therefore they were not considered as risk organs for a therapeutic approach.
The evaluation of the different radiolabeled minigastrin derivatives differing in both, the Cterminal peptide binding moiety and the structural characteristics of the linker, revealed that the compounds with six D-glutamic acid residues within the amino acid chain belong to the most promising substances with an reasonable balance of tumor uptake and decreased kidney reabsorption (11, 12, 16) . The pronounced hydrophilicity of such compounds is most likely the reason for the fast renal excretion and shorter blood half-life of 177 Lu-PP-F11N in comparison to 177 Lu-DOTATATE (β half-life of 163 ± 14 min versus 468 ± 150 min (mean ± SD)) (22) , resulting in a lower tumor radiation dose. Future strategies to achieve higher tumor doses should be investigated and might consist in either increasing tumor uptake (e.g. by upregulation of CCK2R density selectively in MTC) or decreasing stomach uptake (e.g. via a specific diet or by manipulation of gastric acidity).
The main limitation of our study is the low number of evaluated subjects. This might affect the statistical significance of kidney dosimetry with and without SG. But even if SG has a significant nephroprotective effect, it appears unnecessary to expose patients to potentially severe SG- 
